Evidence map›Paper›PMID 38880544›Full record

ReviewSeminars in radiation oncology2024

Navigating the Critical Translational Questions for Implementing FLASH in the Clinic.

Billy W Loo, Ioannis I Verginadis, Brita Singers Sørensen, Anthony E Mascia, John P Perentesis, Albert C Koong, Emil Schüler, Erinn B Rankin, Peter G Maxim, Charles L Limoli and 1 more

Abstract readReview
In one paragraph

Review in Seminars in radiation oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Microenvironmental remodeling in FLASH radiotherapy.Frontiers in cell and developmental biology · 2026
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Effect of FLASH proton therapy on primary bronchial epithelial cell organoids.Clinical and translational radiation oncology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Billy W LooDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA. Electronic address: BWLoo@stanford.edu.
Ioannis I VerginadisDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Brita Singers SørensenDanish Centre for Particle Therapy & Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark.
Anthony E MasciaDivision of Oncology, Cincinnati Children's Hospital and Departments of Pediatrics and Radiation Oncology, College of Medicine, University of Cincinnati, Cincinnati, OH.
John P PerentesisDivision of Oncology, Cincinnati Children's Hospital and Departments of Pediatrics and Radiation Oncology, College of Medicine, University of Cincinnati, Cincinnati, OH.
Albert C KoongDepartment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Emil SchülerDepartment of Radiation Physics, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Erinn B RankinDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA; Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA.
Peter G MaximDepartment of Radiation Oncology, University of California, Irvine School of Medicine, Irvine, CA.
Charles L LimoliDepartment of Radiation Oncology, University of California, Irvine School of Medicine, Irvine, CA.
Marie-Catherine VozeninSecteur Radio-Oncologie et Radiobiologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland; LiRR - laboratory of innovation in radiobiology applied to radiotherapy, Faculty of Medicine, University of Geneva, Geneva, Switzerland; Laboratory of Radiation Oncology, Radiation Oncology Service, Department of Oncology, CHUV Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Funding

Translational Biology CoreP01CA257907 · NCI · STANFORD UNIVERSITY · PI Quynh-Thu Xuan Le · 2022 to 2026
$12.0M
Project 4: Mechanistic Basics of FLASH Effect: Role of O2P01CA244091 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI LIMOLI, CHARLES · 2020 to 2024
$9.6M
Research Supplements to Promote Diversity in Health-Related Research: Preclinical optimization of ultra-high dose rate (FLASH) radiotherapy parameters for translational relevanceR01CA266673 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SCHUELER, EMIL · 2022 to 2025
$3.5M
Effects of FLASH Radiation on Cancer and the Immune ResponseR01CA233958 · NCI · STANFORD UNIVERSITY · PI ENGLEMAN, EDGAR G., LOO, BILLY W · 2019 to 2024
$2.7M
Improving pediatric brain tumor treatments using FLASH radiotherapyR01CA254892 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Charles Limoli · 2021 to 2026
$2.5M
NCI NIH HHS P01 CA244091NCI NIH HHS P01 CA257907NCI NIH HHS R01 CA233958NCI NIH HHS R01 CA254892NCI NIH HHS R01 CA266673
6 · The paper itself

Abstract

The "FLASH effect" is an increased therapeutic index, that is, reduced normal tissue toxicity for a given degree of anti-cancer efficacy, produced by ultra-rapid irradiation delivered on time scales orders of magnitude shorter than currently conventional in the clinic for the same doses. This phenomenon has been observed in numerous preclinical in vivo tumor and normal tissue models. While the underlying biological mechanism(s) remain to be elucidated, a path to clinical implementation of FLASH can be paved by addressing several critical translational questions. Technological questions pertinent to each beam type (eg, electron, proton, photon) also dictate the logical progression of experimentation required to move forward in safe and decisive clinical trials. Here we review the available preclinical data pertaining to these questions and how they may inform strategies for FLASH cancer therapy clinical trials.

Indexed as

NeoplasmsTranslational Research, BiomedicalAnimalsClinical Trials as TopicHumansRadiation Oncology

Identifiers

PMID38880544
PMCPMC12313220

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.